Clayton Irvine, PharmD, MBA, MS, emphasized that optimizing value-based access to cell and gene therapies requires standardized care protocols, coordinated transitions between care settings, careful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback